Deep Genomics nabs $40M round, doubles down on AI and Wilson disease work

January 7, 2020

Canadian drug development company Deep Genomics has got off a $40 million series B round as it looks to double down on its rare genetic disease and artificial intelligence work

‹ Back to Listing